Myrothecoside, a Novel Glycosylated Polyketide from the Terrestrial Fungus<i>Myrothecium</i>sp. GS-17
Songya ZhangInstitut für pharmazeutische Biologie und Biotechnologie; Albert-Ludwigs Universität; Freiburg 79104 GermanyJing ZhuInstitut für pharmazeutische Biologie und Biotechnologie; Albert-Ludwigs Universität; Freiburg 79104 GermanyTao LiuDepartment of Natural Products Chemistry; School of Pharmacy; China Medical University; Shenyang 110001 P. R. ChinaSuzan SamraInstitut für pharmazeutische Biologie und Biotechnologie; Albert-Ludwigs Universität; Freiburg 79104 GermanyHuaqi PanInstitute of Applied Ecology; Chinese Academy of Sciences; Shenyang 110016 P. R. ChinaJiao BaiKey Laboratory of Structure-Based Drug Design & Discovery; Ministry of Education; Shenyang Pharmaceutical University; Shenyang 110016 P. R. ChinaHuiming HuaKey Laboratory of Structure-Based Drug Design & Discovery; Ministry of Education; Shenyang Pharmaceutical University; Shenyang 110016 P. R. ChinaAndreas BechtholdInstitut für pharmazeutische Biologie und Biotechnologie; Albert-Ludwigs Universität; Freiburg 79104 Germany
2016en
ABI
Abstract
Based on the chemical analysis and targeted bioactivity screening, a new polyketide glycoside, myrothecoside, was isolated from a terrestrial halotolerant fungus, Myrothecium sp. GS-17. The structure of myrothecoside was elucidated on the basis of extensive spectroscopic analysis including 1D- and 2D-NMR (1H,1H-COSY, HSQC, HMBC, and NOESY) experiments, combined with mass spectroscopic data and physicochemical properties. This compound exhibited weak cytotoxicity against human leukemia (HL-60) cancer cell with an IG50 value of 63.61 μm, and also antifungal activities against plant pathogenic fungi Rhizoctonia solani and Fusarium oxysporum using standard agar diffusion tests at 20 μg/disk.
Identifiers
Citations and references
Cited by 20 references